Analyses for subgroups of interest of patients with HFpEF likely to be at higher risk of AF (particularly those with older age or obesity) similarly indicated a consistent benefit with SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.